Intima Bioscience, Inc. is advancing a novel approach to treating metastatic non-small cell lung cancer (NSCLC) through the genetic engineering of tumor-infiltrating lymphocytes (TILs) using CRISPR/Cas9 technology to inhibit the CISH checkpoint. This strategy aims to enhance the efficacy of TIL therapy, which has shown promise in other cancers like melanoma. The market for NSCLC therapies is substantial, with increasing demand for innovative treatments that improve patient outcomes. However, the trial has been withdrawn due to recruitment challenges, which may hinder the asset's development timeline and market entry. Competitive analysis indicates that while several companies are exploring TIL therapies and checkpoint inhibitors, the specific targeting of CISH represents a unique proposition that could differentiate Intima's approach if successfully validated.